Frank Borriello

Dr. Borriello is a physician-scientist, with a specialization in immunology, oncology, and clinical pathology. He is a seasoned pharmaceutical executive specializing in the search and evaluation aspects of business development. He began his career as a laboratory immunologist and faculty member at the Brigham and Women’s Hospital, Boston. His initial transition into the biotech/pharmaceutical industry in 1999 placed him in a clinical development role after which he transitioned to an oncology-focused business development career via a 7-year stint as a buy-side biotech analyst in the financial sector predominantly with BB Biotech, a 2.4 Billion Swiss Franc, closed-ended life sciences investment fund. He has over 10 years of experience gained from working in companies such as Millennium, Takeda, Shire, and Baxalta. At Baxalta, where he led the Search and Evaluation Function, he delved into multiple therapeutic areas including oncology, immunology as well as gene and cellular therapies for rare diseases. He obtained his MD, Ph.D. degrees at the Albert Einstein College of Medicine, and his BS in Chemistry from New York University. Dr. Borriello is the recipient of multiple distinguished awards and is the author of more than 30 peer-reviewed publications. From 1991 to 1999, Dr. Borriello was a faculty member at the Brigham and Women’s Hospital (BWH) and Harvard Medical School, first as a pathology resident and chief resident, and then as a pathology research fellow and associate immunologist studying B7/CD28 immune checkpoint pathway using murine KO models. His last position in academia was as Assistant Professor within the Department of Medicine, BWH.